The announcement comes as the wave of infections of the Omicron variant is winding down in the country, but parents are still dealing with school closures and concerns about their unvaccinated children.
New pediatric coronavirus hospitalizations hit a record in the United States in December.
Last month, the FDA approved Pfizer/BioNTech’s booster, or third dose, anti-covid vaccine for children up to 12 years old.
But the rates of vaccination in this age group they are relatively low, less than 22%, according to the Centers for Disease Control and Prevention (CDC), the main US public health agency.
While seeking the green light for children under five to receive two doses of the vaccine, Pfizer and BioNTech will also continue studies on a three-shot regimen, the New York Times noted.
The FDA expects to approve the vaccines for young children in late February. Data on a three-dose regimen would not be submitted until the end of March, the newspaper added.
The companies concluded late last year that low doses of the vaccine provided protection in children up to two years old, but not in children ages two to 5, and announced in December that they would add a third dose to their trials.
Source: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
